Urol. praxi. 2023;24(3):157-164 | DOI: 10.36290/uro.2023.065

Male hypogonadism - summary according to EAU guidelines

MUDr. Aleš Horák
ANDROPHARM medical, s. r. o., Ostrava

The author provides information about the diagnostics of male hypogonadism and testosterone replacement therapy - including the latest recommendations for the patients treatment and monitoring according to the European Association of Urology (EAU).

Keywords: hypogonadism, testosterone, androgens.

Accepted: September 25, 2023; Published: October 2, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Horák A. Male hypogonadism - summary according to EAU guidelines. Urol. praxi. 2023;24(3):157-164. doi: 10.36290/uro.2023.065.
Download citation

References

  1. Salonia A, Bettocchi C, et al. EAU Guidelines on Sexual and Reproductive Health 2022. Available from: https://uroweb.org/guidelines/sexual-and-reproductive-health.
  2. Dohle GR, Arver S, Bettocchi C, et al. EAU Guidelines on Sexual and Reproductive Health 2019. Available from: https://uroweb.org/eau-guidelines/discontinued-topics/male-hypogonadism.
  3. Nieschlag E, et al. Andrology: male reproductive health and dysfunction, 3rd edn. 2010, Heidelberg.
  4. Zámečník L. Androgenní deficit u mužů a jeho léčba testo­steronem v praxi. Urol. praxi. 2020;21(2):72-79. Go to original source...
  5. Khera M, et al. Diagnosis and Treatment of Testosterone Deficiency: Recommendations From the Fourth International Consultation for Sexual Medicine (ICSM 2015). J Sex Med. 2016;13:1787. Go to original source... Go to PubMed...
  6. Lunenfeld B, Mskhalaya G, Kalinchenko S, Tishova Y. Recommendations on the diagnosis, treatment and monitoringof late-onset hypogonadism in men - a suggested update. Aging Male. 2013;16(4):143-150. Go to original source... Go to PubMed...
  7. Tajar A, et al. Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European Male Ageing Study. J Clin Endocrinol Metab. 2010;95:1810. Go to original source... Go to PubMed...
  8. Wu FC, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med. 2010;363:123. Go to original source... Go to PubMed...
  9. Corona G, et al. Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis. Eur J Endocrinol. 2013;168:829. Go to original source... Go to PubMed...
  10. Debruyne FM, et al. Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the Registry of Hypogonadism in Men. BJU Int. 2017;119: 216. Go to original source... Go to PubMed...
  11. Kardoust Parizi M, et al. Oncological safety of testosterone replacement therapy in prostate cancer survivors after definitive local therapy: a systematic literature review and meta-analysis. Urol Oncol. 2019;37:637. Go to original source... Go to PubMed...
  12. Corona G, et al. Testosterone treatment and cardiovascular and venous thromboembolism risk: what is new? J Investig Med. 2017;65:964. Go to original source... Go to PubMed...
  13. Ayele HT, et al. Testosterone replacement therapy and the risk of venous thromboembolism: A Systematic review and meta-analysis of randomized controlled trials. Thromb Res. 2021;199:123. Go to original source... Go to PubMed...
  14. Glueck CJ, et al. Testosterone therapy, thrombosis, thrombophilia, cardiovascular events. Metabolism. 2014;63:989. Go to original source... Go to PubMed...
  15. Malkin CJ, et al. Low serum testosterone and increased mortality in men with coronary heart disease. Heart. 2010;96:1821. Go to original source... Go to PubMed...
  16. Hoyos CM, et al. Body compositional and cardiometabolic effects of testosterone therapy in obese men with severe obstructive sleep apnoea: a randomised placebo-controlled trial. Eur J Endocrinol. 2012;167:531. Go to original source... Go to PubMed...




Urology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.